Design Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-28. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| SR One Capital Fund I Aggregator, LP | 10.7% | 6,526,476 | SCHEDULE 13D/A, 2026-03-11 | 2026-03-09 |
| Sirenia Capital Management LP | 9.5% | 5,963,936 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Logos Global Management LP | 4.4% | 2,500,000 | SCHEDULE 13D/A, 2025-11-18 | 2025-11-14 |
| Point72 Asset Management, L.P. | 3.8% | 2,366,453 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
Logos Global Management LP
The reporting persons filed this Schedule 13D because Dr. William was on the Issuer' board of directors. Dr. William resigned from the Issuer's board of directors on September 9, 2025. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional securities in the open market, through privately negotiated transactions with third parties or otherwise, and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the securities now owned or hereafter acquired by any of them. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the Stock or pledge their interests in the Stock to obtain liquidity. In addition, from time to time the reporting …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-18; the filing has the rest
SR One Capital Fund I Aggregator, LP
Not applicable.Item 4 of the SCHEDULE 13D/A filed 2026-03-11
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-28 | Point72 Asset Management, L.P. | 5.2% | SCHEDULE 13G |
| 2025-11-12 | Logos Global Management LP | 5.7% | SCHEDULE 13D/A |
| 2025-11-18 | Logos Global Management LP | 4.4% | SCHEDULE 13D/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 9.4% | SCHEDULE 13G/A |
| 2026-03-11 | SR One Capital Fund I Aggregator, LP | 10.7% | SCHEDULE 13D/A |
| 2026-05-15 | Point72 Asset Management, L.P. | 4.4% | SCHEDULE 13G/A |
| 2026-06-09 | Point72 Asset Management, L.P. | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Sirenia Capital Management LP | 9.5% | SCHEDULE 13G |
| 2026-08-14 | Point72 Asset Management, L.P. | 3.8% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Design Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.